Fresenius Kabi announced the U.S. launch of its FDA-approved generic Sugammadex Injection, now available in a Simplist ready-to-administer prefilled syringe for use in operating rooms. The launch follows the expiration of exclusivity for Merck's branded Bridion in July 2026. The product is indicated to reverse neuromuscular blockade induced by rocuronium and vecuronium in adults and pediatric patients aged two years and older. Fresenius Kabi offers the 200 mg per 2 mL prefilled syringe, which requires no assembly at the point of care, aiming to streamline medication management and reduce error risk. The product is formulated, filled, and packaged in the U.S., reflecting the company's More in America commitment to domestic manufacturing and supply-chain resilience.
Fresenius SE & Co. KGaAFresenius Kabi launched its FDA-approved generic Sugammadex prefilled syringe in the U.S., expanding its product offering.
Merck & Company IncFresenius Kabi's generic Sugammadex launch after Bridion exclusivity expiration erodes Merck's branded Bridion franchise.
Merck KGaA